Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Paul, Wannamaker"'
Autor:
Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang, Melanie Paff, William R. Spreen, Susan L. Ford
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Long-acting (LA) cabotegravir demonstrated superior efficacy versus daily oral standard-of-care for HIV-1 preexposure prophylaxis. This phase 1 study assessed safety, tolerability, pharmacokinetics, and acceptability of cabotegravir in 47 HIV-negativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d301d99e06799048fa7fb5a85c695283
https://doi.org/10.1128/aac.02057-21
https://doi.org/10.1128/aac.02057-21
Autor:
Ronald D’Amico, Colleen A. McHorney, Maggie Czarnogorski, Jason Flamm, Cindy Garris, Nobuhle Mpofu, Paul Wannamaker, Sonal G. Mansukhani, Paul Benson, Daniela M Chiriboga-Salazar, Blair Thedinger
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir and rilpivirine long-acting (CAB+RPV LA) administered by monthly injection demonstrated non-inferiority compared to standard daily oral antiretroviral therapy (ART) at 48 weeks. This novel treatment offers a less frequent dosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92e0effc2efefa65d1895062fe446cce
http://europepmc.org/articles/PMC7777520
http://europepmc.org/articles/PMC7777520
Autor:
Colleen A. McHorney, Paul Wannamaker, William V. Williams, Larissa Stassek, Carolyn Selenski, Cindy Garris, Leandro Mena, Gary I Sinclair, Maggie Czarnogorski, Michael Wohlfeiler, Ronald D’Amico, David Margolis
Publikováno v:
Open Forum Infectious Diseases
Background CAB+RPV LA administered monthly for HIV treatment is non-inferior to daily oral ART at maintaining HIV suppression but concerns about implementation of this novel treatment paradigm remain. CUSTOMIZE, an implementation-effectiveness study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dd1362e689e7f37d98d476144ecfaa9
http://europepmc.org/articles/PMC7777284
http://europepmc.org/articles/PMC7777284
Autor:
Calvin J. Cohen, Linda Yau, Anthony LaMarca, Paul Wannamaker, Benjamin Young, Mary Beth Wire, Edwin DeJesus, Mark S. Shaefer, Lisa G. Patel, Cindy Vavro
Publikováno v:
HIV Clinical Trials. 11:239-247
ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs). In an effort to better manage toxicities through a reduced dose of RTV, this study compared fosamprenavir (FPV) booste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::117a64b4f8c9848ded9f1176a608848e
https://doi.org/10.1310/hct1105-239
https://doi.org/10.1310/hct1105-239
Autor:
Kimberly Y, Smith, Parul, Patel, Derek, Fine, Nicholaos, Bellos, Louis, Sloan, Philip, Lackey, Princy N, Kumar, Denise H, Sutherland-Phillips, Cindy, Vavro, Linda, Yau, Paul, Wannamaker, Mark S, Shaefer, C, Zurawski
Publikováno v:
AIDS. 23:1547-1556
BACKGROUND Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for initial HIV-1 treatment. This is the first completed, randomized clinical trial to directly comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10966a2a799f5485741ff530b63d62db
https://doi.org/10.1097/qad.0b013e32832cbcc2
https://doi.org/10.1097/qad.0b013e32832cbcc2
Autor:
Philip Lackey, Joseph C. Gathe, Edwin DeJesus, Linda Yau, Christine Katlama, Mark S. Shaefer, Vicente Estrada, Jane Yeo, Benjamin Young, Paul Wannamaker, Schlomo Staszewski, Patrick Yeni, Denise H. Sutherland-Phillips, Joseph J. Eron, Lisa G. Patel, Cindy Vavro
Publikováno v:
The Lancet. 368:476-482
Summary Background Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety to lopinavir-ritonavir when each is combined with two nucleoside revers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac425d03450ade856bcaba3580d24eb6
https://doi.org/10.1016/s0140-6736(06)69155-1
https://doi.org/10.1016/s0140-6736(06)69155-1
Autor:
Britt Stancil, Joseph J. Eron, Scott White, Edwin DeJesus, David A. Margolis, Paul Wannamaker, Mark Johnson
Publikováno v:
Antiviral therapy. 19(1)
Background Fosdevirine (GSK2248761) is a non-nucleoside reverse transcriptase inhibitor with HIV-1 activity against common efavirenz-resistant strains. Two partially blind, randomized, Phase IIb studies were initiated (1 in treatment-naive and 1 in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42ffebebeda854c90b526d1b1c0cce8
https://pubmed.ncbi.nlm.nih.gov/24158593
https://pubmed.ncbi.nlm.nih.gov/24158593
Autor:
Aries Study Team, Lisa L. Ross, Nicholas Bellos, Lisa G. Patel, Denise H. Sutherland-Phillips, Benjamin Young, Daniel Murphy, Kathleen Squires, Edwin DeJesus, Henry H. Zhao, Paul Wannamaker, Mark S. Shaefer
Publikováno v:
HIV clinical trials. 11(2)
The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by simplification to ATV + ABC/3TC in antiretroviral-naïve patients.This report includes a noncomparati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a0af5fc1cb29f5882fc49af5fb469c
https://pubmed.ncbi.nlm.nih.gov/20542844
https://pubmed.ncbi.nlm.nih.gov/20542844
Publikováno v:
AIDS patient care and STDs. 23(11)
Screening for HLA-B 5701 reduces the risk of developing an abacavir hypersensitivity reaction (ABC HSR) and is recommended in all patients before initiating highly active antiretroviral therapy (HAART) with abacavir. Between September 2007 and March
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e0a60939acbe36f849db91919c0e8a4
https://pubmed.ncbi.nlm.nih.gov/19839743
https://pubmed.ncbi.nlm.nih.gov/19839743
Autor:
Qiming Liao, Parul Patel, Mark S. Shaefer, Benjamin Young, Nicholaos C. Bellos, Paul Wannamaker, Kathleen Squires, Daniel S Berger, Edwin DeJesus, Denise H. Sutherland-Phillips
Publikováno v:
AIDS (London, England). 22(13)
A hypersensitivity reaction is associated with abacavir in approximately 2-8% of exposed patients. The frequency of the HLA-B*5701 allele varies across racial groups and significantly correlates with risk of hypersensitivity. Studies in Europe and We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a48cf2d0e5df9d295d15ff18cda32f8d
https://pubmed.ncbi.nlm.nih.gov/18670229
https://pubmed.ncbi.nlm.nih.gov/18670229